Method for preparing glutathione and D-cysteine through double-enzyme coupling
Through dual enzyme coupling catalytic technology, the catalytic synthesis of D-cysteine is solved by catalyzing the mutant glutathione bifunctional synthesizer and polyphosphate kinase, which solves the efficiency and cost of preparing D-cysteine in the prior art. Problem, an efficient and environmentally friendly preparation method is achieved.
Patent Information
- Application Number
- CN202410967119.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-18
- Publication Date
- 2024-11-08
AI Technical Summary
The method for preparing D-cysteine in the prior art has problems such as low yield, poor optical purity, complex reaction conditions, environmental protection and cost control, especially the long reaction time of the enzyme splitting method, complicated steps and low efficiency. , and the asymmetric conversion method requires high temperature to consume a large amount of energy.
Using the preparation method of dual enzyme coupling, genetically engineered bacterial cells with glutathione bifunctional synthase mutants and polyphosphate kinase mutants catalyzed L-glutamate and L-cysteine in buffer Glycine produces glutathione, and D-cysteine is produced at the same time, and efficient, simple and low-cost preparation is achieved by optimizing enzyme activity and reaction conditions.
It provides a green, environmentally friendly, low-cost and efficient method for preparing D-cysteine, which shortens the production cycle, improves the catalytic activity and production efficiency of enzymes, reduces production costs, and has high optical purity of the product.
Smart Images

Figure CN118910193A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of biotechnology, and in particular to a method for preparing glutathione and D-cysteine by double enzyme coupling. Background Art
[0002] D-amino acids are non-natural protein amino acids and are widely used in the production of cosmetics, antibiotics, painkillers, diet pills, anti-cancer and other medical products. Currently, based on the role of D-amino acids in bacterial physiological metabolism, many new medical products are still under development.
[0003] The chemical name of cysteine is 2-amino-3-mercaptopropionic acid, with a molecular formula of C3H2NO2S and a relative molecular mass of 121.12. Cysteine is an aliphatic amino acid, a white crystalline powder, odorless, sour, easily oxidized, easily soluble in water, slightly soluble in ethanol, and insoluble in organic reagents such as ether and benzene. According to different configurations, cysteine is divided into D-type, L-type and DL-type, of which DL-type is the racemic form of cysteine.
[0004] D-cysteine is an important intermediate for the synthesis of the third-generation antibiotic cefuroxime sodium. Cefuroxime sodium has a strong antibacterial effect on Escherichia coli, Streptococcus, Klebsiella, Haemophilus influenzae, Bacteroides, etc. Its effect on Gram-negative bacteria is stronger than other similar drugs. At the same time, D-cysteine hydrochloride is also a strong inhibitor of Escherichia coli and an effective reliever for acute alcohol poisoning.
[0005] At present, the preparation methods of D-cysteine mainly include induced crystallization method, chemical resolution method, enzyme resolution method and asymmetric transformation method.
[0006] (1) Induced crystallization method
[0007] Tadashi et al. obtained DL-cysteine by mixing concentrated ammonia and DL-cysteine hydrochloride, adding acetone to react to obtain DL-2,2-dimethylthiazolidine-4-carboxylic acid, forming a supersaturated solution at 40°C, adding D-2,2-dimethylthiazolidine-4-carboxylic acid as a seed to induce crystallization, filtering the precipitate, and hydrolyzing the product to obtain D-cysteine with a yield of 2%. Although this method is simpler than other methods, it has a low yield and the optical purity of the product does not meet the ideal requirements.
[0008] (2) Chemical separation method
[0009] Zhang Tao et al. dissolved DL-cysteine hydrochloride monohydrate in water, then made an aqueous solution of a certain amount of NaOH and D-(-)-mandelic acid, heated and stirred to completely dissolve D-(-)-mandelic acid, mixed with DL-cysteine hydrochloride aqueous solution, placed the reaction solution in an ice bath, and filtered to obtain D-cysteine-D-mandelic acid when a large amount of crystals were precipitated; added dilute hydrochloric acid solution to the obtained D-cysteine-D-mandelic acid, heated to completely dissolve, cooled to precipitate D-cysteine hydrochloride, the specific rotation of the product was -7.4°, and the single reaction recovery rate was 25.6%. This method achieves separation according to its different chemical properties, and the optical purity is also improved, but due to the complex reaction conditions in the splitting process, it is not conducive to environmental protection and cost control, and has certain limitations in actual industrial production.
[0010] (3) Enzymatic splitting method
[0011] Enzymatic splitting has the advantages of mild reaction conditions, simple operation steps and low cost, and has therefore attracted widespread attention.
[0012] Koito et al. used an aqueous solution of S-benzyl-DL-cysteine hydrochloride as a substrate and an enzyme extracted from pig liver as a catalyst. The reaction was carried out at 37°C for 4 hours to hydrolyze the S-benzyl-L-cysteine hydrochloride in the substrate, retaining S-benzyl-D-cysteine, which was separated and then subjected to a debenzylation reaction to obtain D-cysteine. This method has a cumbersome reaction process and a long cycle. During the reaction, the substrate concentration must not be too high, and the reaction efficiency is low. At most, only 50% S-benzyl-D-cysteine can be obtained.
[0013] (4) Asymmetric transformation method
[0014] Shiariw et al. placed DL-cysteine, R-tartaric acid, acetone and salicylaldehyde in acetic acid, reacted at 77°C for 2.7 hours, then stirred in an ice bath, filtered, washed, dried, and then stirred in ethanol at 60°C for 1 hour to obtain D-cysteine with an optical purity of 100% and a yield of 80%.
[0015] The above methods for preparing D-cysteine all have some disadvantages and shortcomings. Although the induced crystallization method is simple to operate, its yield is low, only 2%, and the ideal optical purity cannot be obtained. The reaction conditions in the chemical splitting method are complicated, requiring a large amount of chemical reagents, which is not conducive to environmental protection and cost control, and the single reaction recovery rate is low. Although the enzyme splitting method is simple to operate, the reaction time is long, the operation steps are cumbersome, and the reaction efficiency is also low. The asymmetric transformation method requires high temperature reaction conditions, consumes a lot of energy, and has high requirements for equipment. Therefore, it is imperative to develop a process for preparing D-cysteine efficiently, simply and at low cost. Summary of the invention
[0016] The purpose of the present invention is to overcome the deficiencies in the prior art and provide a method for preparing glutathione and D-cysteine by double enzyme coupling.
[0017] In order to achieve the purpose of the present invention, the present invention will be implemented by adopting the following technical solutions.
[0018] A method for preparing glutathione and D-cysteine by dual enzyme coupling, characterized in that the method comprises the following steps: using a buffer solution containing 12.0-17.2 g / L of sodium L-glutamate, 5.4-8.0 g / L of glycine, 14.2-20.6 g / L of DL-cysteine, 1.3-1.8 g / L of adenosine triphosphate and 50-150 g / L of sodium hexametaphosphate as a reaction system, adding genetically engineered bacterial cells A or a crude enzyme solution A having glutathione bifunctional synthetase mutant activity and genetically engineered bacterial cells B or a crude enzyme solution B having polyphosphate kinase mutant activity, reacting at pH 7-9 and 30-45° C., catalyzing L-glutamate, L-cysteine and glycine to produce glutathione, and simultaneously preparing D-cysteine.
[0019] As a preferred embodiment of the present invention, the genetically engineered bacterial cell A is formed by using Escherichia coli BL21 (DE3) as a host, plasmid pET-28a as an expression vector, and carrying a mutant gene of glutathione bifunctional synthetase.
[0020] As a preferred embodiment of the present invention, the glutathione bifunctional synthetase mutant gene can encode a glutathione bifunctional synthetase mutant.
[0021] As a preferred embodiment of the present invention, the glutathione bifunctional synthetase mutant is formed by mutation of one or more amino acid residue sites in the glutathione bifunctional synthetase shown in the amino acid sequence SEQID NO.1, wherein the mutated amino acid residue sites include mutation of isoleucine at position 17 to histidine, mutation of alanine at position 48 to cysteine, mutation of threonine at position 94 to isoleucine, mutation of arginine at position 123 to phenylalanine and mutation of leucine at position 137 to serine.
[0022] As a preferred embodiment of the present invention, the genetically engineered bacterial cell B is formed by using E. coli BL21 (DE3) as a host and plasmid pET-28a as an expression vector, carrying a polyphosphate kinase mutant gene.
[0023] As a preferred embodiment of the present invention, the polyphosphate kinase mutant gene can encode a polyphosphate kinase mutant.
[0024] As a preferred embodiment of the present invention, the polyphosphate kinase mutant is formed by mutation of one or more amino acid residue sites in the polyphosphate kinase shown in the amino acid sequence SEQ ID NO.3, wherein the mutated amino acid residue sites include mutation of glutamic acid at position 27 to leucine, mutation of valine at position 38 to serine, mutation of isoleucine at position 101 to threonine, mutation of glycine at position 122 to phenylalanine and mutation of leucine at position 237 to alanine.
[0025] As a preferred embodiment of the present invention, the crude enzyme solution A is obtained by subjecting the whole cells of the genetically engineered bacterial cells A to ultrasonic or high-pressure homogenization.
[0026] As a preferred embodiment of the present invention, the crude enzyme solution B is obtained by subjecting the whole cells of the genetically engineered bacterial cells B to ultrasonic or high-pressure homogenization.
[0027] As a preferred embodiment of the present invention, the substrates for the catalytic reaction are DL-cysteine, L-glutamic acid, glycine, sodium hexametaphosphate, ATP and magnesium ions.
[0028] As a preferred embodiment of the present invention, the substrate DL-cysteine of the catalytic reaction can be prepared by chemical synthesis or racemization reaction, can also be prepared by biological method, and can also be derived from crude DL-cysteine or its hydrochloride.
[0029] Application of a glutathione bifunctional synthetase mutant and a polyphosphate kinase mutant or a genetically engineered bacterium expressing the glutathione bifunctional synthetase mutant and the polyphosphate kinase mutant in the preparation of glutathione.
[0030] Compared with the prior art, the invention has the beneficial effect of providing a new method for preparing D-cysteine with high efficiency, simplicity and low cost.
[0031] (1) The present invention provides a mutant of glutathione bifunctional synthetase StGshF and a mutant of polyphosphate kinase CgPPK. Specifically, the amino acid sequences of the glutathione bifunctional synthetase StGshF mutant and the polyphosphate kinase CgPPK mutant undergo specific mutations, thereby improving the enzyme catalytic activity and production efficiency.
[0032] (2) The present invention provides a new reaction system, which utilizes the coupled catalysis of a glutathione bifunctional synthetase mutant and a polyphosphate kinase mutant, takes DL-cysteine as a substrate, catalyzes L-glutamate, L-cysteine and glycine to produce glutathione, and simultaneously produces D-cysteine.
[0033] (3) The present invention provides a green, environmentally friendly, low-cost production method for preparing D-cysteine. The traditional method for preparing D-cysteine is complicated and time-consuming. The enzymatic method provided by the present invention has the advantages of being green, environmentally friendly, mild and efficient, greatly shortening the production cycle and reducing production costs. BRIEF DESCRIPTION OF THE DRAWINGS
[0034] Figure 1 The present invention provides a reaction route for the method for preparing glutathione and D-cysteine by dual enzyme coupling. DETAILED DESCRIPTION
[0035] The technical solution of the present invention will be clearly and completely described below in combination with the embodiments of the present invention and the accompanying drawings. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0036] The experimental methods, detection methods and preparation methods disclosed in the present invention all adopt conventional molecular biology, biochemistry, chromatin structure and analysis, analytical chemistry, cell culture, recombinant DNA technology and related fields in the technical field, and can be specifically operated according to Molecular Cloning: A Laboratory Manual (Fourth Edition).
[0037] The correspondence between the Chinese full names, three-letter abbreviations and single-letter abbreviations of the 20 natural amino acids in the present invention is shown in Table 1:
[0038] Table 1
[0039] Amino Acid Chinese Name Three letter abbreviation Single letter abbreviation Arginine Arg R Histidine His H Lysine Lys K Aspartic acid Asp D Glutamate Glu E Serine Ser S Threonine Thr T Asparagine Asn N Glutamine Gln Q Cysteine Cys C Glycine Gly G Proline Pro P Alanine Ala A Isoleucine Ile I Valine Vla V Leucine Leu L Methionine Met M Phenylalanine Phe F Tyrosine Tyr Y Tryptophan Trp W
[0040] Example 1: Construction of bifunctional glutathione synthetase (StGshF) expression vector
[0041] The bifunctional glutathione synthetase (StGshF) gene from Streptococcus thermophilus S. thermophilus (GenBank: ADD63794.1) was selected, and its amino acid sequence is shown in SEQ ID NO.1 in the sequence listing, and its nucleotide sequence is shown in SEQ ID NO.2 in the sequence listing.
[0042] After the PCR product of the nucleotide sequence shown in SEQ ID NO.2 was purified, it was double digested with Nco I and Xho I endonucleases, and then ligated with the pET-28a vector digested with the same enzymes using T4 ligase at 16°C overnight, and transformed into E. coli BL21 (DE3) competent cells. It was spread on LB plates containing 1.5% agar (containing 50 μg / mL kanamycin), and the recombinant vector was named pET-28a-StGshF.
[0043] Example 2: Determination of site-directed mutagenesis sites
[0044] The specific method is as follows:
[0045] (1) Target site design and analysis
[0046] a. Homology Modeling
[0047] The homology modeling of the bifunctional glutathione synthetase sequence was performed using the SWISS-MODEL online software to obtain its three-dimensional structure. Multiple sequence alignment was performed using MEGA7.0, and the model was visualized and analyzed using PyMol.
[0048] b. Model Validation
[0049] The models were evaluated using PROCHECK and Verify-3D programs. Ramachandran plot was used to illustrate the ratio of two dihedral angles (φ and ψ) in the peptide plane to indicate the allowed and unallowed conformations of amino acid residues, and the stereochemical reliability of the model was evaluated by Psi / Phi Ramachandran plot calculated by PROCHECK. The compatibility of protein side chain amino acid residues was evaluated by Verify-3D software, and at least 80% of the amino acid residues passed the verification if the score was ≥0.2.
[0050] c. Molecular docking of enzyme and ligand
[0051] The molecular docking program in the Discovery studio software was used for molecular docking. The molecules were docked into the binding pocket of the enzyme based on the principle of interaction hot zone matching to observe the interaction between them.
[0052] d. Selection of amino acids to be mutated and their replacement
[0053] Based on the homologous multiple sequence alignment of bifunctional glutathione synthetases from different sources, conservative amino acid sites were excluded, and amino acids at non-conservative sites were selected as pseudo-mutant amino acids, which were replaced with amino acids with similar properties or high frequency in other bifunctional glutathione synthetases to form a series of pseudo-mutant enzymes.
[0054] e. Acquisition of mutation sites
[0055] The program was used to perform molecular docking simulations on various pseudo-mutant enzymes and ligands, and the binding free energy of various docking complexes was calculated. The lower the value, the higher the affinity between the receptor and the ligand, thereby improving the enzyme activity and obtaining the mutation site.
[0056] Example 3: Preparation and expression of StGshF combined site mutants
[0057] Using SDM PCR technology, the original plasmid pET-28a-StGshF was used as a template for site-directed mutagenesis to obtain a recombinant plasmid pET-28a-StGshF-X carrying a mutant encoding a bifunctional glutathione synthetase, wherein the site-directed mutagenesis method is as follows:
[0058] PCR program: 98℃ pre-denaturation for 30s; 98℃ denaturation for 10s, 64℃ annealing for 30s, 72℃ extension for 6min, 20 cycles; 72℃ extension for 10min. Dpn I digestion: PCR product 19μL, Dpn I 0.5μL, 37℃ 1h. Then the obtained recombinant vector pET-28a-StGshF-X was transformed into DH5α competent cells, single clones were picked, and DNA sequencing analysis was performed by Beijing Qingke Biotechnology Co., Ltd. to determine the correct transformant.
[0059] The primer sequences used to obtain the StGshF mutant in the present invention are shown in Table 2:
[0060] Table 2
[0061] Primer name sequence A48C-F GCTGTCTGGGCTGACGTAGCTTT A48C-R AAAGCTACGTCAGCCCAGACAGC I17H-F CCAGCCCGCATCTGCAGGCAAAT I17H-R ATTTGCCTGCAGAATCGGGCTGG T94I-F CCGTAGCATTGCCATCGATGAAGTGCT T94I-R AGCACTTCATCGATGGCAATGCTACGG L137S-F AATATGGCACCAAAAGTCAGGCAATTA L137S-R TAATTGCCTGACTTTTGGTGCCATATT R123F-F TGATTTTGAATTCCATTATCGCAATT R123F-R AATTGCGATAATGGAATTCAAAATCA
[0062] The plasmid with the correct sequencing was transferred into BL21 (DE3) competent cells, and a single colony was picked and inoculated into a test tube (10 mL LB) containing 50 μg / mL kanamycin for overnight culture, then transferred to 50 mL LB medium and cultured at 37°C and 200 r / min until OD 600 IPTG was added to a final concentration of 0.1 mmol / L and the culture was continued for 10 h. The fermentation liquid was centrifuged at 8000 r / min for 10 min, and the supernatant was removed. The bacterial precipitate was retained and resuspended in water to OD 600 About 20, ultrasonically disrupted for 15 minutes, centrifuged to remove the precipitate, and the supernatant was used for SDS-PAGE analysis. The results showed that these mutant proteins were expressed normally.
[0063] Example 4: StGshF enzyme activity assay
[0064] Under the catalysis of StGshF, the substrates sodium glutamate, glycine and cysteine use ATP to provide energy to generate glutathione (GSH). The amount of product GSH is measured to calculate the enzyme activity of StGshF.
[0065] The enzyme activity unit (IU) is defined as the amount of enzyme required to catalyze the production of 1 μmol of glutathione per unit time at 30°C and pH 8.0.
[0066] The composition and concentration of the StGshF enzyme activity assay reaction system are shown in Table 3:
[0067] Table 3
[0068] Reaction system Final concentration pH 8.0 Tris-HCl 500mM Glycine 240mM L-Glutamic Acid 180mM DL-Cysteine 240mM <![CDATA[MgCl2]]> 40mM ATP 40mM Enzymes 30 μg water Make up to 500 μL
[0069] Enzyme activity assay reaction steps: the above reaction system was reacted at 30°C for 5 min, then an equal volume of 3 mol / L HCl was added to terminate the reaction, and the GSH content was determined by centrifugation at 12000 r / min for 5 min.
[0070] GSH content detection method: The GSH content was detected using a Wondasil C18 column (4.6×250 mm, GL Sciences Inc., Japan) HPLC system (Shimadzu, Kyoto, Japan) at 25°C and 210 nm. Mobile phase: Phosphate buffer (6.8 g of sodium dihydrogen phosphate and 2.2 g of sodium heptane sulfonate were dissolved in 1000 mL of water and the pH was adjusted to 3.0 with phosphoric acid) / methanol (96 / 4) as the mobile phase, and the injection volume was 10 μL.
[0071] The relative enzyme activity determination results of the wild-type strain (WT) and different site combination mutants (G1-G7) are shown in Table 4:
[0072] Table 4
[0073] name Mutation site Relative enzyme activity WT - 100.0% G1 I17 123.1% G2 I17H-R123F 131.7% G3 I17H-A48C 136.0% G4 I17H-A48C-R123F 152.7% G5 I17H-A48C-T94I 158.0% G6 I17H-A48C-T94I-R123F 166.3% G7 I17H-A48C-T94I-R123F-L137S 184.6%
[0074] From the results in Table 4, it can be seen that the enzyme activity of the mutant I17H-A48C-T94I-R123F-L137S obtained in the present invention is significantly increased compared with the enzyme activity of the wild type, and the enzyme activity is increased by 1.8 times.
[0075] Example 5: Construction of polyphosphate kinase (CgPPK) expression vector
[0076] The polyphosphate kinase (CgPPK) gene from Corynebacterium glutamicum C. glutamicum (GenBank: MT081053.1) was selected, and its amino acid sequence is shown in SEQ ID NO.3 in the sequence listing, and its nucleotide sequence is shown in SEQ ID NO.4 in the sequence listing.
[0077] After the PCR product of the nucleotide sequence shown in SEQ ID NO.4 was purified, it was double digested with Nco I and Xho I endonucleases, and then ligated with the pET-28a vector digested with the same enzymes using T4 ligase at 16°C overnight, and transformed into E. coli BL21 (DE3) competent cells. Spread on LB plates containing 1.5% agar (containing 50 μg / mL kanamycin), and the recombinant vector was named pET-28a-CgPPK.
[0078] Example 6: Determination of site-directed mutagenesis sites
[0079] The specific method is as follows:
[0080] (1) Target site design and analysis
[0081] a. Homology Modeling
[0082] The homology modeling of the polyphosphate kinase sequence was performed using the SWISS-MODEL online software to obtain its three-dimensional structure. Multiple sequence alignment was performed using MEGA7.0, and the model was visualized and analyzed using PyMol.
[0083] b. Model Validation
[0084] The models were evaluated using PROCHECK and Verify-3D programs. Ramachandran plot was used to illustrate the ratio of two dihedral angles (φ and ψ) in the peptide plane to indicate the allowed and unallowed conformations of amino acid residues, and the stereochemical reliability of the model was evaluated by Psi / Phi Ramachandran plot calculated by PROCHECK. The compatibility of protein side chain amino acid residues was evaluated by Verify-3D software, and at least 80% of the amino acid residues passed the verification if the score was ≥0.2.
[0085] c. Molecular docking of enzyme and ligand
[0086] The molecular docking program in the Discovery studio software was used for molecular docking. The molecules were docked into the binding pocket of the enzyme based on the principle of interaction hot zone matching to observe the interaction between them.
[0087] d. Selection of amino acids to be mutated and their replacement
[0088] Based on the homologous multiple sequence alignment of polyphosphate kinases from different sources, conservative amino acid sites were excluded, and amino acids at non-conservative sites were selected as pseudo-mutant amino acids, which were replaced with amino acids with similar properties or high frequency in other bifunctional glutathione synthetases to form a series of pseudo-mutant enzymes.
[0089] e. Acquisition of mutation sites
[0090] The program was used to perform molecular docking simulations on various pseudo-mutant enzymes and ligands, and the binding free energy of various docking complexes was calculated. The lower the value, the higher the affinity between the receptor and the ligand, thereby improving the enzyme activity and obtaining the mutation site.
[0091] Example 7: Preparation and expression of CgPPK combination site mutants
[0092] Using SDM PCR technology, the original plasmid pET-28a-CgPPK was used as a template for site-directed mutagenesis to obtain a recombinant plasmid pET-28a-CgPPK-X carrying a polyphosphate kinase mutant, wherein the site-directed mutagenesis method is as follows:
[0093] PCR program: 98℃ pre-denaturation for 30s; 98℃ denaturation for 10s, 64℃ annealing for 30s, 72℃ extension for 6min, 20 cycles; 72℃ extension for 10min. Dpn I digestion: PCR product 19μL, Dpn I 0.5μL, 37℃ 1h. Then the obtained recombinant vector pET-28a-CgPPK-X was transformed into BL21(DE3) competent cells, single clones were picked, and DNA sequencing analysis was performed by Beijing Qingke Biotechnology Co., Ltd. to determine the correct transformant.
[0094] The primer sequences used to obtain the CgPPK mutants in the present invention are shown in Table 5:
[0095] Table 5
[0096] Primer name sequence E27L-F CAAGACCGCGTACCTAAAAGAGCTGAA E27L-R TTCAGCTCTTTTAGGTACGCGGTCTTG V38S-F CAAGCGGAGCTGAGTGACCTGCAGCAATG V38S-R CATTGCTGCAGGTCACTCAGCTCCGCTTG I101T-F CCAACGTTATACTGAAAAGCTGCCGAC I101T-R GTCGGCAGCTTTTCAGTATAACGTTGG G122F-F CAACCGTGCGTTTGTGGAACGTGTTATG G122F-R CATAACACGTTCCACAAACGCACGGTTG L237A-F GCCACCTGGCGAGCACCATCCCGTATG L237A-R CATACGGGATGGTGCTCGCCAGGTGGC
[0097] The plasmid with the correct sequencing was transferred into BL21 (DE3) competent cells, and a single colony was picked and inoculated into a test tube (10 mL LB) containing 50 μg / mL kanamycin for overnight culture, then transferred to 50 mL LB medium and cultured at 37°C and 200 r / min until OD 600 IPTG was added to a final concentration of 0.1 mmol / L and the culture was continued for 10 h. The fermentation liquid was centrifuged at 8000 r / min for 10 min, and the supernatant was removed. The bacterial precipitate was retained and resuspended in water to OD 600 About 20, ultrasonically disrupted for 15 minutes, centrifuged to remove the precipitate, and the supernatant was used for SDS-PAGE analysis. The results showed that these mutant proteins were expressed normally.
[0098] Example 8: CgPPK enzyme activity assay
[0099] The substrate ADP and polyphosphate polyP6 generate ATP under the catalysis of CgPPK. The amount of product ATP is measured to calculate the enzyme activity of CgPPK.
[0100] The enzyme activity unit (IU) is defined as the amount of enzyme required to catalyze the production of 1 μmol ATP per unit time at 30°C and pH 8.0.
[0101] The composition and concentration of the CgPPK enzyme activity assay reaction system are shown in Table 6:
[0102] Table 6
[0103] Reaction system Final concentration pH 8.0 Tris-HCl 100mM ADP 100mM <![CDATA[polyP6]]> 100mM <![CDATA[MgCl2]]> 50mM Enzymes 30 μg water Make up to 500 μL
[0104] CgPPK enzyme activity assay reaction steps: the above reaction system was reacted at 30°C for 5 min, then an equal volume of 3 mol / L HCl was added to terminate the reaction, and the ATP content was determined by centrifugation at 12000 r / min for 5 min.
[0105] ATP content detection method: HPLC system (Shimadzu, Kyoto, Japan) with Wondasil C18 column (4.6×250 mm, GL Sciences Inc., Japan) was used to detect ATP production at 25°C and 210 nm. Mobile phase: phosphate buffer (6.8 g of sodium dihydrogen phosphate and 2.2 g of sodium heptane sulfonate were dissolved in 1000 ml of water and the pH was adjusted to 3.0 with phosphoric acid) / methanol (96 / 4) as the mobile phase, and the injection volume was 10 μL.
[0106] The relative enzyme activity determination results of the wild-type strain (WT) and the multi-point combination mutants (P1-P7) are shown in Table 7:
[0107] Table 7
[0108] name Mutation site Relative enzyme activity WT - 100.0% P1 V38S 127.4% P2 E27L-V38S 135.1% P3 V38S-I101T 138.9% P4 E27L-V38S-I101T 160.7% P5 E27L-V38S-I101T-G122F 178.2% P6 E27L-V38S-I101T-L237A 183.3% P7 E27L-V38S-I101T-G122F-L237A 209.6%
[0109] From the results in Table 7, it can be seen that the enzyme activity of the mutant E27L-V38S-I101T-G122F-L237A obtained in the present invention is significantly increased compared with the enzyme activity of the wild type, and the enzyme activity is increased by 2.1 times.
[0110] Example 9: Preparation of glutathione and D-cysteine by dual enzyme coupling
[0111] The cells containing the polyphosphate kinase mutant and the glutathione bifunctional synthetase mutant were added to a 1000 mL reaction system, which contained 20.6 g / L DL-cysteine, 17.2 g / L sodium L-glutamate, 8.0 g / L glycine, and 1.8 g / L polyP65, 8.0 g / L MgSO4·7H2O, and 1.8 g / L ATP. The reaction temperature was 30°C, and the pH was controlled at 8.5 with a 2 mol / L sodium hydroxide aqueous solution. The reaction was completed after 20 hours, and the GSH concentration was 24.8 g / L and the D-cysteine concentration was 10.3 g / L.
[0112] Example 10: Preparation of glutathione and D-cysteine by dual enzyme coupling
[0113] The bacterial cells containing polyphosphate kinase mutant and glutathione bifunctional synthetase mutant were added to a 2250 mL reaction system containing 15.8 g / L DL-cysteine, 13.3 g / L sodium L-glutamate, 5.9 g / L glycine, 8.0 g / L polyP63, 5.9 g / L MgSO4·7H2O and 1.3 g / L ATP. The reaction was carried out at 37°C, and the pH was controlled at 9.0 with a 2 mol / L sodium hydroxide aqueous solution. The reaction was terminated after 18 hours, and the final GSH concentration was 19.0 g / L and the D-cysteine concentration was 7.9 g / L.
[0114] Example 11: Preparation of glutathione and D-cysteine by dual enzyme coupling
[0115] The bacterial cells containing the polyphosphate kinase mutant and the glutathione bifunctional synthetase mutant were added to a 2500 mL reaction system containing 17.8 g / L DL-cysteine, 14.9 g / L sodium L-glutamate, 6.7 g / L glycine, 3.8 g / L polyP64, 6.8 g / L MgSO4·7H2O and 1.5 g / L ATP. The reaction was carried out at 37°C, and the pH was controlled at 8.5 using a 2 mol / L sodium hydroxide aqueous solution. The final GSH concentration was 21.2 g / L, and the D-cysteine concentration was 8.9 g / L.
[0116] Example 12: Preparation of glutathione and D-cysteine by dual enzyme coupling
[0117] The crude enzyme solutions containing polyphosphate kinase mutant and glutathione bifunctional synthetase mutant were added to a 2000 mL reaction system containing 15.2 g / L DL-cysteine, 12.8 g / L sodium L-glutamate, 5.7 g / L glycine, 36.8 g / L polyP6, 5.7 g / L MgSO4·7H2O and 1.3 g / L ATP. The reaction was carried out at 37°C, and the pH was controlled at 8.5 using a 2 mol / L sodium hydroxide aqueous solution. The final GSH concentration was 18.3 g / L, and the D-cysteine concentration was 7.6 g / L.
[0118] Example 13: Preparation of glutathione and D-cysteine by dual enzyme coupling
[0119] The bacterial cells containing the polyphosphate kinase mutant and the glutathione bifunctional synthetase mutant were added to a 1500 mL reaction system containing 16.1 g / L DL-cysteine, 13.5 g / L sodium L-glutamate, 6.0 g / L glycine, 8.6 g / L polyP63, 6.0 g / L MgSO4·7H2O and 1.4 g / L ATP. The reaction was carried out at 37°C, and the pH was controlled at 8.5 using a 2 mol / L sodium hydroxide aqueous solution. The final GSH concentration was 19.3 g / L, and the D-cysteine concentration was 8.0 g / L.
[0120] Example 14: Preparation of glutathione and D-cysteine by dual enzyme coupling
[0121] The crude enzyme solutions containing polyphosphate kinase mutant and glutathione bifunctional synthetase mutant were added to a 1500 mL reaction system containing 17.0 g / L DL-cysteine, 14.3 g / L sodium L-glutamate, 6.4 g / L glycine, 1.2 g / L polyP64, 6.4 g / L MgSO4·7H2O and 1.5 g / L ATP. The reaction was carried out at 37°C, and the pH was controlled at 8.0 using a 2 mol / L sodium hydroxide aqueous solution. The final GSH concentration was 20.4 g / L, and the D-cysteine concentration was 8.48 g / L.
[0122] Example 15: Preparation of glutathione and D-cysteine by dual enzyme coupling
[0123] The bacterial cells containing the polyphosphate kinase mutant and the glutathione bifunctional synthetase mutant were added to a 2000 mL reaction system containing 14.2 g / L DL-cysteine, 12.0 g / L sodium L-glutamate, 5.4 g / L glycine, 4.8 g / L polyP63, 5.4 g / L MgSO4·7H2O and 1.5 g / L ATP. The reaction was carried out at 38°C, and the pH was controlled at 8.5 using a 2 mol / L sodium hydroxide aqueous solution. The final GSH concentration was 16.8 g / L and the D-cysteine concentration was 7.0 g / L.
[0124] Example 16: Preparation of glutathione and D-cysteine by dual enzyme coupling
[0125] The crude enzyme solutions containing the polyphosphate kinase mutant and the glutathione bifunctional synthetase mutant were added to a 1800 mL reaction system containing 16.8 g / L DL-cysteine, 14.4 g / L sodium L-glutamate, 5.9 g / L glycine, 4.8 g / L polyP63, 5.4 g / L MgSO4·7H2O and 1.3 g / L ATP. The reaction was carried out at 36°C, and the pH was controlled at 8.2 using a 2 mol / L sodium hydroxide aqueous solution. The final GSH concentration was 19.6 g / L, and the D-cysteine concentration was 8.3 g / L.
[0126] Example 17: Preparation of glutathione and D-cysteine by dual enzyme coupling
[0127] The crude enzyme solutions containing polyphosphate kinase mutant and glutathione bifunctional synthetase mutant were added to a 2500 mL reaction system containing 15.4 g / L DL-cysteine, 12.5 g / L sodium L-glutamate, 5.6 g / L glycine, 6.1 g / L polyP63, 5.6 g / L MgSO4·7H2O and 1.3 g / L ATP. The reaction was carried out at 45°C, and the pH was controlled at 7.5 using a 2 mol / L sodium hydroxide aqueous solution. The final GSH concentration was 18.4 g / L, and the D-cysteine concentration was 7.5 g / L.
[0128] Example 18: Preparation of glutathione and D-cysteine by dual enzyme coupling
[0129] The bacterial cells containing the polyphosphate kinase mutant and the glutathione bifunctional synthetase mutant were added to a 2200 mL reaction system containing 19.8 g / L DL-cysteine, 16.6 g / L sodium L-glutamate, 7.5 g / L glycine, 8.3 g / L polyP64, 7.5 g / L MgSO4·7H2O and 1.7 g / L ATP. The reaction was carried out at 40°C, and the pH was controlled at 8.0 using a 2 mol / L sodium hydroxide aqueous solution. The final GSH concentration was 23.6 g / L, and the D-cysteine concentration was 9.7 g / L.
[0130] Sequence Listing
[0131] SEQ ID NO.1
[0132] GSTLNQLLQKLEATSPILQANFGIERESLRVDRQGQLVHTPHPSCLGARSFHPYIQTDFCEFQMELITPVAKSTTEARRFLGAITDVAGRSIATDEVLWPLSMPPRLKAEEIQVAQLENDFERHYRNYLAEKYGTKLQAISGIHYNMELGKDLVEALFQESGQTDMIAFKNALYLKLAQNYLRYRWVITYLFGASPIAEQGFFDQEVPEPVRSFRNSDHGYVNKEEIQVSFVSLEDYVSAIETYIEQGDLNAEKEFYSAVRFRGQKVNRSFLDKGITYLEFRNFDLNPFERIGISQTTMDTVHLLILAFLWLDSPENVDQALAQGHALNEKIALSHPLEPLPSEAKTQDIVTALDQLVQHFGLGDYHQDLVKQVKAAFADPNQTLSAQLLPYIKDKSLAEFALNKALAYHDYDWTAHYALKGYEEMELSTQMLLFDAIQKGIHFEILDEQDQFLKLWHQDHVEYVKNGNMTSKDNYVVPLAMANKTVTKKILADAGFPVPSGDEFTSLEEGLAYYPLIKDKQIVVKPKSTNFGLGISIFQEPASLDNYQKALEIAFAEDTSVLVEEFIPGTEYRFFILDGRCEAVLLRVAANVIGDGKHTIRELVAQKNANPLRGRDHRSPLEIIELGDIEQLMLAQQGYTPDDILPEGKKVNLRRNSNISTGGDSIDITETMDSSYQELAAAMATSMGAWACGVDLIIPDETQIATKENPHCTCIELNFNPSMYMHTYCAEGPGQAITTKILDKLFPEIVAGQT。
[0133] SEQ ID NO.2
[0134]
[0135] SEQ ID NO.3
[0136] MGRKKKDGQNLPDFRKNPPKLDKTAYEKELKRLQAELVDLQQWVVETGARVVIVMEGRDAAGKGSAIKRITQYLNPRSARIELPTPNSREKGQWYFQRYIEKLPTAGEIVIFDRSWYNRAGVERVMGFCTSQEYRRFLHQAPIFERLLVEDGIHLRKYWF SVSDEEQIERFEDRLSDPLRRWKLSPMDLQSITRWEDYSRAKDEMFIHTDIPSAPWYVESEDKKRSRINVISHLLSTPYEKIDRPLPEIPHRPDSESDYVRPPRDEFRYVPDAAHLEEERIKKEEAKKAKKPAKAAGKNSDKKKSSSGGKGKKSKKK。
[0137] SEQ ID NO.4
[0138] ATGGGCCGTAAGAAAAAGGACGGTCAGAACCTGCCGGATTTTCGTAAAAACCCGCCGAAACTGGACAAGACCGCGTACGAAAAAGAGCTGAAGCGTCTGCAAGCGGAGCTGGTTGACCTGCAGCAATGGGTGGTTGAAACCGGTGCGCGTGTGGTTATCGTTATGGAAGGTCGTGATGCGGCGGGTAAAGGCAGCGCGATCAAGCGTATTACCCAGTATCTGAACCCGCGTAGCGCGCGTATTGAGGCGCTGCCGACCCCGAACAGCCGTGAAAAAGGCCAGTGGTACTTCCAACGTTATATTGAAAAGCTGCCGACCGCGGGCGAGATCGTGATTTTTGATCGTAGCTGGTACAACCGTGCGGGTGTGGAACGTGTTATGGGCTTCTGCACCAGCCAGGAGTATCGTCGTTTCCTGCACCAAGCGCCGATCTTTGAACGTCTGCTGGTTGAGGACGGCATTCACCTGCGTAAATACTGGTTCAGCGTTAGCGATGAGGAACAGATCGAACGTTTTGAGGACCGTCTGAGCGATCCGCTGCGTCGTTGGAAACTGAGCCCGATGGACCTGCAAAGCATTACCCGTTGGGAAGACTACAGCCGTGCGAAGGATGAGATGTTTATCCACACCGACATTCCGAGCGCGCCGTGGTATACCGTGGAAAGCGAGGATAAAAAGCGTAGCCGTATCAACGTTATTAGCCACCTGCTGAGCACCATCCCGTATGAAAAGATTGATCGTCCGCTGCCGGAGATCCCGCACCGTCCGGACAGCGAAAGCGATTACGTTCGTCCGCCGCGTGACGAGTTCCGTTATGTGCCGGATGTTGCGGCGCACCTGGAGGAAGAGCGTATTAAAAAGGAAGAGAAAGCGAAAAAGGCGAAAAAGCCGGCGAAAGCGGCGGGCAAGAACAGCGACAAAAAGAAAAGCAGCGGTGGCAAGGGCAAGAAAAAGAGCAAAAAGTAA。
[0139] The technical solution of the present invention is described in detail above in conjunction with the embodiments / drawings, but the present invention is not limited to the above technical solution. For ordinary technicians in this technical field, after knowing the contents recorded in the present invention, they can make several equivalent changes and substitutions without departing from the principle of the present invention. These equivalent changes and substitutions should also be regarded as belonging to the protection scope of the present invention.
Claims
1. A method for preparing glutathione and D-cysteine by dual enzyme coupling, characterized in that: The method comprises the following steps: using a buffer solution containing 12.0-17.2 g / L of sodium L-glutamate, 5.4-8.0 g / L of glycine, 14.2-20.6 g / L of DL-cysteine, 1.3-1.8 g / L of adenosine triphosphate and 50-150 g / L of sodium hexametaphosphate as a reaction system, adding genetically engineered bacterial cells A having glutathione bifunctional synthetase mutant activity or its crude enzyme solution A and genetically engineered bacterial cells B having polyphosphate kinase mutant activity or its crude enzyme solution B, reacting at pH 7-9 and 30-45° C., catalyzing L-glutamic acid, L-cysteine and glycine to produce glutathione, and simultaneously preparing D-cysteine.
2. The method for preparing glutathione and D-cysteine by dual enzyme coupling according to claim 1, characterized in that: The genetically engineered bacterial cell A is formed by using E. coli BL21 (DE3) as a host, plasmid pET-28a as an expression vector, and carrying a glutathione bifunctional synthetase mutant gene.
3. The method for preparing glutathione and D-cysteine by dual enzyme coupling according to claim 2, characterized in that: The glutathione bifunctional synthetase mutant gene can encode a glutathione bifunctional synthetase mutant.
4. The method for preparing glutathione and D-cysteine by dual enzyme coupling according to claim 3, characterized in that: The glutathione bifunctional synthetase mutant is formed by mutation of one or more amino acid residue sites in the glutathione bifunctional synthetase shown in the amino acid sequence SEQ ID NO.1, wherein the mutated amino acid residue sites include mutation of isoleucine at position 17 to histidine, mutation of alanine at position 48 to cysteine, mutation of threonine at position 94 to isoleucine, mutation of arginine at position 123 to phenylalanine and mutation of leucine at position 137 to serine.
5. The method for preparing glutathione and D-cysteine by dual enzyme coupling according to claim 1, characterized in that: The genetically engineered bacterial cell B is formed by using E. coli BL21 (DE3) as a host, plasmid pET-28a as an expression vector, and carrying a polyphosphate kinase mutant gene.
6. The method for preparing glutathione and D-cysteine by dual enzyme coupling according to claim 5, characterized in that: The polyphosphate kinase mutant gene can encode a polyphosphate kinase mutant.
7. The method for preparing glutathione and D-cysteine by dual enzyme coupling according to claim 6, characterized in that: The polyphosphate kinase mutant is formed by mutation of one or more amino acid residue sites in the polyphosphate kinase shown in the amino acid sequence SEQ ID NO.3, wherein the mutated amino acid residue sites include mutation of glutamic acid at position 27 to leucine, mutation of valine at position 38 to serine, mutation of isoleucine at position 101 to threonine, mutation of glycine at position 122 to phenylalanine and mutation of leucine at position 237 to alanine.
8. The method for preparing glutathione and D-cysteine by dual enzyme coupling according to claim 1, characterized in that: The crude enzyme solution A is obtained by subjecting the whole cells of the genetically engineered bacterial cells A to ultrasonic or high-pressure homogenization.
9. The method for preparing glutathione and D-cysteine by dual enzyme coupling according to claim 1, characterized in that: The crude enzyme solution B is obtained by subjecting the whole cells of the genetically engineered bacterial cells B to ultrasonic or high-pressure homogenization.
10. Use of a glutathione bifunctional synthetase mutant and a polyphosphate kinase mutant or a genetically engineered bacterium expressing a glutathione bifunctional synthetase mutant and a polyphosphate kinase mutant in the preparation of glutathione.
